Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669082 | 1.00 | CA2 (0.38) | CA2 | |
| SCHEMBL24292276 | 1.00 | CA2 (0.38) | CA2 | |
| SCHEMBL15203096 | 1.00 | CA2 (0.38) | CA2 | |
| SCHEMBL2195577 | 1.00 | CA2 (0.38) | CA2 | |
| Formic Acid SCHEMBL15493899 | 0.93 | CA2 (0.34) | CA2 | |
| Formic Acid SCHEMBL20699833 | 0.93 | CA2 (0.34) | CA2 | |
| SCHEMBL2660 | 0.92 | — | — | |
| Ammonia Solution, Strong SCHEMBL28778364 | 0.89 | — | — | |
| SCHEMBL29290936 | 0.89 | — | — | |
| SCHEMBL7202080 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487494-B2 | Cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA A/S (DK) | 2016-11-08 | — | — | US | claimed |
| CN-101970394-B | Novel cyclic hydrocarbon compounds for the treatment of diseases | LEO PHARMA AS | 2015-05-27 | — | — | CN | claimed |
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-12-16 | — | — | US | claimed |
| EP-2234961-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-10-06 | — | — | EP | claimed |
| WO-2009065406-A2 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2009-05-28 | — | — | WO | claimed |
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | claimed |
| EP-1027351-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-1999021860-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 1999-08-05 | — | — | WO | claimed |
| WO-1999021860-A1 | PHENANTHROLINE DERIVATIVES | FIBROGEN, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| EP-0271443-B1 | N,N'-DISUBSTITUTED UREAS AND PROCESS FOR THEIR PRODUCTION | CIBA-GEIGY AG (CH) | 1990-10-17 | — | — | EP | claimed |
| US-4940811-A | METAL SCAVENGING PHARMACEUTICAL | CIBA-GEIGY CORPORATION (US) | 1990-07-10 | — | — | US | claimed |
| US-4764523-A | Novel carbonic acid esters | CIBA-GEIGY CORPORATION (US) | 1988-08-16 | — | — | US | claimed |
| EP-0271443-A1 | N,N'-disubstituted ureas and process for their production | CIBA-GEIGY AG (CH) | 1988-06-15 | — | — | EP | claimed |
| US-4698329-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-06 | — | — | US | claimed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | claimed |
| WO-1983002613-A1 | TRISUBSTITUTED OXAZO COMPOUNDS | SALLMANN, ALFRED | 1983-08-04 | — | — | WO | claimed |
| EP-0084756-A1 | Trisubstituted oxaza compounds | CIBA-GEIGY AG (CH) | 1983-08-03 | — | — | EP | claimed |
| US-4148791-A | DISPERSE DYES | SANDOZ LTD. (CH) | 1979-04-10 | — | — | US | claimed |
| JP-58164644-A | — | — | None | — | — | JP | disclosed |
| US-4173647-A | ANTIMICROBIAL | BOEHRINGER INGELHEIM GMBH (DE) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317582-A1 | NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR THE TREATMENT OF DISEASES | ARNT, AHR, CYP27A1 | CA2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.